Aquestive Therapeutics (AQST) Enterprise Value (2017 - 2026)

Aquestive Therapeutics' Enterprise Value history runs 10 years deep, the most recent figure standing at -$110.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 61.29% year-over-year to -$110.7 million; the TTM figure through Mar 2026 stood at -$110.7 million (down 61.29% YoY), while the FY2025 annual figure was -$121.2 million, down 69.36% from the prior year.
• Enterprise Value was -$110.7 million for Q1 2026 at Aquestive Therapeutics, up from -$121.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$14.7 million in Q1 2022 to a low of -$129.1 million in Q3 2025.
• Historically, Enterprise Value has averaged -$58.9 million across 5 years, with a median of -$60.5 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value jumped 48.31% in 2022, then sank 300.56% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$27.3 million in 2022, then increased by 12.47% to -$23.9 million in 2023, then tumbled by 199.71% to -$71.5 million in 2024, then sank by 69.36% to -$121.2 million in 2025, then gained by 8.61% to -$110.7 million in 2026.
• The last three Enterprise Value figures came in at -$110.7 million (Q1 2026), -$121.2 million (Q4 2025), and -$129.1 million (Q3 2025), per Business Quant data.